» Articles » PMID: 8452359

Analysis of Vancomycin Entry into Pulmonary Lining Fluid by Bronchoalveolar Lavage in Critically Ill Patients

Overview
Specialty Pharmacology
Date 1993 Feb 1
PMID 8452359
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Vancomycin penetration into the fluid lining the epithelial surface of the lower respiratory tract was studied by performing fiberoptic bronchoscopy with bronchoalveolar lavage on 14 critically ill, ventilated patients who had received the drug for at least 5 days. The apparent volume of epithelial lining fluid (ELF) recovered by bronchoalveolar lavage was determined by using urea as an endogenous marker. Vancomycin levels in ELF ranged from 0.4 to 8.1 micrograms/ml (mean, 4.5 micrograms/ml), while the mean simultaneous level of the drug in plasma was 24 micrograms/ml (range, 9 to 37.4 micrograms/ml). There was a significant relationship (r = 0.64, P < 0.02) between vancomycin levels in plasma and those in ELF, with a correlation whose slope (0.15) indicated that the blood-to-ELF ratio of drug penetration was 6:1. Using the albumin concentration in ELF as a marker of lung inflammation, we found that vancomycin penetration was higher in patients with ELF albumin values of > or = 3.4 mg/ml than in patients with normal values (< 3.4 mg/ml) (P < 0.02). These results suggest that the vancomycin distribution includes the ELF of the lower respiratory tract at a concentration that is dependent upon the levels in blood and the alveolar capillary membrane protein permeability. These concentrations were well above the MICs for most staphylococci and enterococci.

Citing Articles

Analysis of Nirmatrelvir Entry into Pulmonary Lining Fluid in Patients with COVID-19: A Unique Perspective to Explore and Understand the Target Plasma Concentration of 292 ng/mL in Antiviral Activity.

Zhang W, Xia L, Yuan Z, Jiao Y, Wang Z Immun Inflamm Dis. 2024; 12(11):e70075.

PMID: 39545673 PMC: 11565441. DOI: 10.1002/iid3.70075.


Prediction of tissue exposures of polymyxin-B, amikacin and sulbactam using physiologically-based pharmacokinetic modeling.

Wu M, Feng K, Wu X, Liu C, Zhu S, Martins F Front Microbiol. 2024; 15:1435906.

PMID: 39435440 PMC: 11491386. DOI: 10.3389/fmicb.2024.1435906.


Pharmacokinetics of vancomycin in sputum of intubated patients: Optimized intravenous delivery vs. inhaled therapy.

Palmer L, Monteforte M, Smaldone G Br J Clin Pharmacol. 2024; 91(1):127-133.

PMID: 39235040 PMC: 11671327. DOI: 10.1111/bcp.16225.


Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant Bacteremia: A Systematic Review and Meta-Analysis.

Kawasuji H, Nagaoka K, Tsuji Y, Kimoto K, Takegoshi Y, Kaneda M Antibiotics (Basel). 2023; 12(4).

PMID: 37107059 PMC: 10135165. DOI: 10.3390/antibiotics12040697.


How to Use Nebulized Antibiotics in Severe Respiratory Infections.

Gorham J, Taccone F, Hites M Antibiotics (Basel). 2023; 12(2).

PMID: 36830177 PMC: 9952454. DOI: 10.3390/antibiotics12020267.


References
1.
Theodore J, Robin E, Gaudio R, Acevedo J . Transalveolar transport of large polar solutes (sucrose, inulin, and dextran). Am J Physiol. 1975; 229(4):989-96. DOI: 10.1152/ajplegacy.1975.229.4.989. View

2.
Stevens R, TERES D, SKILLMAN J, Feingold D . Pneumonia in an intensive care unit. A 30-month experience. Arch Intern Med. 1974; 134(1):106-11. View

3.
Hunninghake G, Gadek J, Kawanami O, Ferrans V, Crystal R . Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol. 1979; 97(1):149-206. PMC: 2042387. View

4.
Rennard S, Crystal R . Fibronectin in human bronchopulmonary lavage fluid. Elevation in patients with interstitial lung disease. J Clin Invest. 1982; 69(1):113-22. PMC: 371174. DOI: 10.1172/jci110421. View

5.
Schwenzer K, Wang C, Anhalt J . Automated fluorescence polarization immunoassay for monitoring vancomycin. Ther Drug Monit. 1983; 5(3):341-5. DOI: 10.1097/00007691-198309000-00017. View